AbCellera Biologics (ABCL) Total Liabilities (2020 - 2026)

AbCellera Biologics has reported Total Liabilities for 7 years, with the latest figure at $369.0 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 14.88% year-over-year to $369.0 million; the trailing twelve-month figure through Mar 2026 stood at $369.0 million (up 14.88% YoY), and the FY2025 full-year result was $390.0 million, up 28.11% from the prior year.
• Total Liabilities for Q1 2026 stood at $369.0 million, down from $390.0 million in the prior quarter.
• The five-year high for Total Liabilities was $395.0 million in Q2 2025, with the low at $289.4 million in Q1 2023.
• Historically, Total Liabilities has averaged $340.8 million across 5 years, with a median of $333.2 million in 2024.
• Annual changes were most pronounced in 2022 — Total Liabilities jumped 124.49% — and 2023, when it retreated 24.78%.
• AbCellera Biologics' Total Liabilities stood at $307.6 million in 2022, then advanced by 9.15% to $335.8 million in 2023, then decreased by 9.32% to $304.5 million in 2024, then grew by 28.11% to $390.0 million in 2025, then dropped by 5.39% to $369.0 million in 2026.
• The last three Total Liabilities figures came in at $369.0 million (Q1 2026), $390.0 million (Q4 2025), and $392.0 million (Q3 2025), per Business Quant data.